Medicenna Therapeutics Corp has seen a slight decline this week, despite recent advancements in its clinical programs and patent acquisitions.
Medicenna Therapeutics Corp (MDNA.TO) has experienced a 2.13% drop in its stock price over the past week, closing at C$0.43. This follows a month of positive momentum where the stock gained 22.67%. The company has made headlines recently with significant updates regarding its financial results and patent protections, which may influence investor sentiment moving forward.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$42.46M
52W high
$1.97
52W low
$0.34
1W change
-2.13%
Beta
1.96
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 595.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+595.7% Upside
Current Price
C$0.46
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
62.1%
Annualized
90-Day Vol
65.2%
Annualized
Trend (90d)
+28.3%
Annualized drift
90d Mean
C$0.51
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.48 | C$0.38 – C$0.59 |
| 60 trading days | C$0.49 | C$0.36 – C$0.67 |
| 90 trading days | C$0.51 | C$0.35 – C$0.74 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: While Medicenna has reported promising advancements in its clinical programs and secured new patents, the recent stock performance suggests caution. Investors should consider the company's ongoing financial challenges and the broader market context.
C$0.43 Closing Price, Reflecting a 2.13% Decline This Week
Medicenna's stock is currently trading at a significant discount compared to its 52-week high of C$1.97, with analysts projecting an average target price of C$3.20, implying a potential upside of over 644%.
Bull case
Recent positive developments in Medicenna's Superkine platform and the potential of its MDNA11 treatment suggest a bright outlook. Analysts are optimistic, projecting an average target price that is significantly higher than the current trading price, indicating strong growth potential.
Bear case
However, the company's high beta of 1.96 points to increased volatility, and its significant year-to-date decline of 54.00% raises concerns about its financial health and market confidence.
Recent Price Action
Medicenna Therapeutics Corp has seen a decline of 2.13% in its stock price this week, closing at C$0.43. This follows a more favorable month, where the stock gained 22.67%. Despite this recent downturn, the stock remains significantly lower than its 52-week high of C$1.97.
Advertisement
Company News and Developments
Recent headlines indicate that Medicenna has reported its fiscal year 2026 financial results, showcasing advancements in its Superkine platform and ongoing clinical trials. Furthermore, the company has secured new patents in the U.S. for its IL-2, IL-4, and IL-13 Superkine platforms, which may enhance its competitive position in the market. Additionally, Medicenna closed a public offering that raised approximately CDN$4.44 million to support its lead programs.
Technical Picture
From a technical standpoint, Medicenna is currently trading above its 50-day moving average of C$0.40, which indicates a 7.9% premium. However, it is significantly below its 200-day moving average of C$0.71, reflecting a 39.1% discount. The stock has a beta of 1.96, suggesting higher volatility compared to the market. The latest trading volume of 84,645 shares is notably higher than the 20-day average volume of 51,242 shares, indicating increased trading activity.
Insider Activity
No recent insider activity has been reported for Medicenna Therapeutics Corp, indicating that there have been no significant insider transactions that could influence investor sentiment.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
